DMU Research Symposium
The Research Symposium aims to recognize the research efforts of those at Des Moines University (DMU) and in the surrounding medical and scientific community by providing a forum for the collaboration of ideas, the production of new hypotheses, and to demonstrate to the attendees the critical role that research plays in the advancement of health care.
DMU faculty, staff, students, residents, alumni, external researchers and health professionals from the Des Moines area and surrounding medical and scientific community are invited to participate and present. All students, faculty, and residents are encouraged to develop research projects to be presented at the Symposium.
Mark Rupp, MD
- Professor, Department of Internal Medicine, Section of Infectious Diseases, University of Nebraska Medical Center
- Medical Director, Department of Healthcare Epidemiology-Infection Control
- Medical Director – Interim, Antimicrobial Stewardship Program The Nebraska Medical Center
- Medical Director, Clinical Trials Office
Dr. Rupp is a Professor and Chief of the Division of Infectious Diseases in the Department of Internal Medicine at the University of Nebraska Medical Center. He is the Medical Director of The Nebraska Medical Center Department of Infection Control & Epidemiology and co-Director of the Antimicrobial Stewardship Program.
Dr. Rupp received his medical degree from Baylor College of Medicine, Houston, Texas and holds a B.S. degree in Chemical Engineering from the University of Texas, Austin, Texas. He underwent internship and residency training in Internal Medicine and completed Fellowship training in Infectious Diseases at Virginia Commonwealth University.
He is a Diplomate, American Board of Internal Medicine, and in the subspecialty area of Infectious Diseases. He is a Fellow of the American College of Physicians (ACP), the Infectious Diseases Society of America (IDSA), and the Society for Hospital Epidemiology of America (SHEA). He is a Past-President of SHEA and is a past-president of ASM Division L (Infection Control/Hospital Epidemiology). Dr Rupp has served as a consultant for the US Food and Drug Administration as well as the Centers for Disease Control and Prevention.
Dr. Rupp has published over 300 articles, chapters and abstracts. He frequently presents papers at national and international meetings, serves as a guest lecturer, and is an active teacher and researcher. Dr. Rupp’s research interests are in the areas of staphylococcal disease, healthcare-associated infections, and antimicrobial resistance.
Relative to the content of this CME activity, Dr. Rupp indicated he is a consultant for 3M, C. R. Bard, Inc., and Semprus BioSciences. He is also the principal investigator or working directly with 3M, Mölnlycke Health Care, and Sanofi.
|9 am||Poster Viewing|
When Opportunity Knocks... Conduct a Study: Clinical and Translational Research in Infection Prevention
Case-Based Panel Discussion
|2:30 pm||Oral Abstract Presentations|
|3:45 pm||Poster Abstract Presentations|
No commercial interest provided financial support for this continuing education activity.
Continuing Education Credit
- DO: Des Moines University and the AOA Council on Continuing Medical Education approve this program for a maximum of 1.5 hours of AOA Category 1-A CME credits and 2.0 hours of AOA Category 2-B CME credits.
- Nurse: Des Moines University continuing education (provider #112) is approved by the Iowa Board of Nursing as an accredited provider. This program has been reviewed and approved for a maximum of 4.5 continuing education contact hours.
- DPM: Des Moines University (DMU) is approved by the Council on Podiatric Medical Education as a sponsor of continuing education in podiatric medicine. DMU has approved this live activity for a maximum of 3.75 continuing education contact hour(s).
- Other: Attendees will be given a certificate of participation for a maximum 3.75 continuing education hours.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content for this program and the selection of speakers are responsibilities of the program director. Firms providing financial support did not have input in these areas.
- 1.50 AOA Category 1A
- 2.00 AOA Category 2B
- 3.75 CE Contact Hour(s)
- 3.75 CPME
- 4.50 IBON